Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Acquired Hemophilia A Clinical Trial

Official title:
Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Status No longer available

Clinical Trial Summary

To provide emergency access to OBI-1 for patients with Acquired Hemophilia and a serious bleeding episode who do not have access to an active clinical study site associated with the OBI-1-301 study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01968655
Study type	Expanded Access
Source	Takeda
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03700229` - Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A	Phase 2
Completed	`NCT04580407` - Study of TAK-672 in Participants With Acquired Hemophilia A	Phase 2/Phase 3
Completed	`NCT01178294` - Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A	Phase 2/Phase 3
Completed	`NCT02610127` - Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Completed	`NCT03384277` - Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab	Phase 4
Completed	`NCT03199794` - Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
Recruiting	`NCT05345197` - Emicizumab in Patients With Acquired Hemophilia A	Phase 2